FDA advisors unanimously reject Intarcia ' s embattled type 2 diabetes treatment
I2o Therapeutics CEO Kurt Graves set out on Thursday to make a case to a panel of the FDA’s expert advisors that the benefits of his company’s twice-rejected implant to treat type 2 diabetes outweigh its risks — but the committee wasn’t convinced. The FDA’s Endocrinologic…#kurtgraves #fda #2diabetes #metabolic #unlock
Source: Reuters: Health - Category: Consumer Health News Source Type: news